Overall, despite limited available evidence, inhibitors of EIF4G or EIF4G1/EIF4E interactions could be emerging as novel strategies to indirectly target mTOR signalling in HNSCC. This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.